Incretin Atlas › Molecules › RGT-075
RGT-075
GLP-1 (small molecule) · oral · Regor
Summary
- Also known as
- Regor
- Mechanism
- GLP-1 (small molecule)
- Route
- oral
- Company
- Regor
- Highest development stage
- phase 2
- Status (as of data cut)
- Phase 2b (36 weeks) presented at EASD 2026 verify
- Next milestone
- Phase 3
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RGT-075 phase 2b | RGT-075 180 mg oral | obesity | 36 | — | −10.4 % vs −1.6 % Δ −8.8 pp | −10.4 % vs −1.6 % Δ −8.8 pp | — | — | — | — | — | — | −9.9 vs +0.0 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- RGT-075 180 mg oral · weight_eff · Abstract, Results
treatment with RGT-075 at 180 mg resulted in a least-square mean percent body-weight reduction of 10.4%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: RGT-075. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/rgt-075/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.